Mannkind (MNKD) Accumulated Expenses (2010 - 2026)
Mannkind (MNKD) reported Accumulated Expenses of $29.0 million for Q1 2026, up 554.16% year-over-year from $4.4 million in Q1 2025, and down 55.09% quarter-over-quarter from $64.6 million in Q4 2025.
Mannkind (MNKD) Accumulated Expenses (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 17 years of Accumulated Expenses data on file, last reported at $29.0 million in Q1 2026.
- Accumulated Expenses for Q1 2026 came in at $29.0 million, up 554.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.0 million (up 554.16% YoY), and the FY2025 annual result was $64.6 million, changed N/A from the prior year.
- Accumulated Expenses eased to $29.0 million in Q1 2026 per MNKD's latest filing, from $64.6 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $64.6 million in Q4 2025 and troughed at $93000.0 in Q2 2023.
- A 5-year average of $17.2 million and a median of $13.1 million in 2024 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses sank 98.47% in 2023, then soared 13508.6% in 2024.
- A 5-year view of Accumulated Expenses shows it stood at $846000.0 in 2022, then soared by 4868.79% to $42.0 million in 2023, then dropped by 11.06% to $37.4 million in 2024, then surged by 72.87% to $64.6 million in 2025, then tumbled by 55.09% to $29.0 million in 2026.
- Business Quant data shows MNKD's Accumulated Expenses at $29.0 million in Q1 2026, $64.6 million in Q4 2025, and $1.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Mannkind | 1.13 Bn | 995.19 Mn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.03 Mn |
| Dec 31, 2025 | 64.63 Mn |
| Sep 30, 2025 | 1.11 Mn |
| Jun 30, 2025 | 13.45 Mn |
| Mar 31, 2025 | 4.44 Mn |
| Sep 30, 2024 | 37.39 Mn |
| Jun 30, 2024 | 12.66 Mn |
| Mar 31, 2024 | 680,000.00 |
| Dec 31, 2023 | 42.04 Mn |
| Sep 30, 2023 | 14.77 Mn |
| Jun 30, 2023 | 93,000.00 |
| Mar 31, 2023 | 16.45 Mn |
| Dec 31, 2022 | 846,000.00 |
| Sep 30, 2022 | 30.35 Mn |
| Jun 30, 2022 | 6.07 Mn |
| Mar 31, 2022 | 729,000.00 |
| Dec 31, 2021 | 14.02 Mn |
| Sep 30, 2021 | 10.97 Mn |
| Jun 30, 2021 | 1.06 Mn |
| Mar 31, 2021 | 4.49 Mn |